Pipeline of Assets Available for Partnering Opportunities
The SapVax platform is a versatile and powerful tool for development of a pipeline of peptide-based cancer vaccines. SapVax’s lead NY-ESO-1 targeting candidate (SVX-ESO) is in late-stage preclinical development with a near-term path to the clinic. SapVax’s SVX-NEO program, aimed at creating personalized neoantigen vaccines, is in the discovery stage. The SapVax vaccine approach has high potential for synergy with other novel immunotherapies, including combination with checkpoint inhibitors, CAR-T, and other cellular therapies.